Skip to main content
. 2024 Mar 1;35(3):212–222. doi: 10.5152/tjg.2024.23071

Table 3.

Median OS and PFS in the Total Cohort and Subgroups


Total P BCLC C P
TACE-L
(n = 51)
TACE
(n = 51)
TACE-L
(n = 36)
TACE
(n = 35)
Median OS (months) 12.17 10.17 .042 11.5 8.03 .009
Median PFS (months) 3.33 2.9 .007 3.1 2.9 .012

OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization.